Stocks›Healthcare›BBNX

BBNX

BETA BIONICS, INC.

NasdaqResearch view

Healthcare · Surgical & Medical Instruments & Apparatus · Small-cap · SEC EDGAR FY 2025-12-31

Price history

Chart: TradingView’s own feed · page prices: 1D EOD

🔒 Click to interact · scroll moves the page

Snapshot

SEC EDGAR · FY 2025-12-31

SectorHealthcare

Market Cap$745.5M

Enterprise Value$713.8M

Income$-73.2M

Sales$100.3M

Book/sh$6.39

Cash/sh$0.70

Dividend TTM—

Payout—

Employees—

IPO—

Quick Ratio7.96

Current Ratio8.66

Debt/Eq—

EPS (ttm)$-1.81

EPS this Y79.0%

EPS past 3/5Y—

Sales past 3/5Y—

EPS Y/Y TTM79.0%

Sales Y/Y TTM53.9%

Shs Outstand44.99M

ROA-22.3%

ROE-25.5%

ROIC-28.0%

Gross Margin55.4%

Oper. Margin-71.5%

Profit Margin-73.0%

Every figure here is filed with the SEC. Valuation and estimate metrics (P/E, PEG, EV/EBITDA, price targets, forward EPS) are omitted until our market-data feed is licensed for display — we’d rather show fewer numbers than blank ones. Deeper lines (cash flow, balance sheet) below.

Revenue & Earnings — fiscal year

$12.0M

2023

$65.1M

2024

$100.3M

2025

Financials — annual

SEC EDGAR · last 3 FY · tap a row to explain it

USD	FY2023	FY2024	FY2025
Revenue	$12.0M	$65.1M	$100.3M
Gross Profit	$6.3M	$35.9M	$55.5M
Operating Income	$-35.9M	$-45.3M	$-71.7M
Net Income	$-44.1M	$-54.8M	$-73.2M
Diluted EPS	$-8.31	$-8.60	$-1.81
Operating Cash Flow	$-32.4M	$-48.3M	$-50.9M
Free Cash Flow	$-32.8M	$-51.7M	$-56.2M

Deep dive

Computed from the SEC EDGAR multi-year statements

Operating leverage — margins

GrossOperatingNet

FY25 cash-flow waterfall

Cash-flow detail unavailable in this filing.

—

Follow the news. Track the move.

BBNX story timeline

Company updates and connected market context, with the dated price move attached.

Stories

Direct

Sector context/Regulation

Sep 14

Beta Bionics Announces FDA Clearance of Mint™, the Company’s Transformative Patch Pump, and Unveils 3D Intelligence™ as its Next-Generation Insulin Dosing Algorithm

Beta Bionics said the FDA cleared its Mint patch pump, a reusable-and-disposable insulin-delivery system with CGM integration and smartphone control. The clearance gives BBNX a new commercial product and a potential route to expand beyond its existing insulin-delivery market, but the announcement does not disclose launch timing or financial targets.

Price history unavailable

GlobeNewswire · 3h ago

View both sides →

Follow the news. Track the move.